Early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) significantly enhance survival of severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis: results of the CAMELIA clinical trial
2011

Early vs. Late HAART for HIV Patients with Tuberculosis

Sample size: 661 publication Evidence: high

Author Information

Author(s): François-Xavier Blanc, Sok Thim, Laureillard Didier, Borand Laurence, Rekacewicz Claire, Nerrienet Eric, Madec Yoann, Marcy Olivier, Chan Sarin, Prak Narom, Kim Chindamony, Kim Lak Khemarin, Hak Chanroeurn, Dim Bunnet, Im Sin Chhun, Sun Sath, Guillard Bertrand, Sar Borann, Vong Sirenda, Fernandez Marcelo, Fox Lawrence, Delfraissy Jean-François, Goldfeld Anne E

Primary Institution: Institut Pasteur International Network

Hypothesis

Does early initiation of HAART improve survival in severely immunosuppressed HIV-infected adults with tuberculosis compared to late initiation?

Conclusion

Starting HAART 2 weeks after TB treatment significantly improves survival in severely immunosuppressed HIV-infected adults.

Supporting Evidence

  • 661 patients were enrolled in the study.
  • 149 patients were known dead by May 13, 2010.
  • Enhanced survival was observed in the early treatment group.

Takeaway

If you start HIV treatment sooner after getting tuberculosis, you are more likely to survive.

Methodology

Open-labelled randomized clinical trial comparing early vs. late HAART initiation after TB treatment in treatment-naïve adults.

Participant Demographics

Median age of 35 years, CD4+ cell count ≤ 200 cells/mm3.

Statistical Information

P-Value

0.004

Statistical Significance

p=0.004

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication